Aktis Oncology, Inc. (AKTS) SEC Filings & Earnings Calls
EquiReason read 11 Aktis Oncology, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Cash, Cash Equivalents and Marketable Securities $517M; Collaboration Revenue $3M; R&D Expenses $25M.
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 874.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
13 Aug 20268-K · 2.02Cash, Cash Equivalents and Marketable Securities $517M; Collaboration Revenue $3M; R&D Expenses $25Mearningsopen
Figures in the filing · each found in the filing text
| Cash, Cash Equivalents and Marketable Securities · Q2-2026 | $517M | |
| Collaboration Revenue · Q2-2026 | $3M | |
| R&D Expenses · Q2-2026 | $25M | |
| G&A Expenses · Q2-2026 | $7M | |
| Net Loss · Q2-2026 | $-24M |
Risks flagged
Pre-commercial stage with no product revenue; net loss of $24.1M; reliance on clinical trial success and regulatory approvals.
“Net loss was $24.1 million for the quarter ended June 30, 2026” · word for word
Clinical development risk: early-stage pipeline with no approved products; data readouts expected in 2027.
“Expect preliminary data from the ongoing Phase 1b NECTINIUM-2 clinical trial in the first quarter of 2027” · word for word
13 Aug 202610-QQuarterly net loss widened to $24.1M as R&D spend increased; no product revenue; cash runway into 2029.earningsopen
Figures in the filing · each found in the filing text
| Collaboration revenue · Q2-2026 | $3M | +111% y/y |
| Net loss · Q2-2026 | $-24M | +34% y/y |
| Research and development expenses · Q2-2026 | $25M | +36% y/y |
| Cash, cash equivalents, and marketable securities · 2026-06-30 | $517M | |
| Accumulated deficit · 2026-06-30 | $-199M | |
| Net cash used in operating activities · H1-2026 | $-45M | +33% y/y |
| IPO net proceeds · Q1-2026 | $334M |
Risks flagged
No product revenue; reliance on collaboration and capital markets
“We do not have any products approved for commercial sale and have not generated any revenues from product sales.” · word for word
Significant operating losses and accumulated deficit
“We have incurred significant operating losses in every year since inception and we expect to continue to incur substantial losses for the foreseeable future.” · word for word
Need for additional capital
“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word
11 May 202610-QCash, cash equivalents and marketable securities $538M; Net loss $-18M (+22% y/y); Research and development expenses $20M (+26% y/y); Guidance: Cash runway into 2029open
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $539M | |
| Net loss · Q1-2026 | $-18M | +22% y/y |
| Research and development expenses · Q1-2026 | $20M | +26% y/y |
| General and administrative expenses · Q1-2026 | $6M | +58% y/y |
| IPO net proceeds · Q1-2026 | $334M | |
| Accumulated deficit · Q1-2026 | $175M |
Guidance
Cash runway into 2029
Cash runway guidance reaffirmed; no revenue guidance.
Risks flagged
Clinical Development Risk
“We have incurred significant operating losses in every year since inception and we expect to continue to incur substantial losses for the foreseeable future.” · word for word
Funding Dependency
“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word
11 May 20268-K · 2.02Cash, cash equivalents and marketable securities $538M; Collaboration revenue $3M (+129% y/y); R&D expenses $20Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · total · Q1-2026 | $539M | |
| Collaboration revenue · total · Q1-2026 | $3M | +129% y/y |
| R&D expenses · total · Q1-2026 | $20M | |
| IPO gross proceeds · total · Q1-2026 | $365M |
Risks flagged
Clinical trial failure risk for both AKY-1189 and AKY-2519.
“Both programs are in Phase 1b with no efficacy data yet; preliminary data expected in 2027.”
No approved products or product revenue; dependent on partnership and financing.
“Revenue only from collaboration; no product sales.”
16 Apr 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Board composition change: loss of two directors may reduce diversity of perspectives, but new appointment adds relevant expertise.
“Resignations of Helen S. Kim and Oleg Nodelman; appointment of Glenn Gormley.” · word for word
30 Mar 202610-KNet loss $-64M; Accumulated deficit $157M; Cash, cash equivalents and marketable securities $227Mopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-64M | |
| Accumulated deficit · 2025-12-31 | $157M | |
| Cash, cash equivalents and marketable securities · 2025-12-31 | $227M | |
| IPO net proceeds · 2026-01 | $335M | |
| Employees · 2025-12-31 | 79 |
Risks flagged
No approved products; pre-revenue
“We have no products licensed for commercial sale and have not generated any revenues from product sales to date” · word for word
Clinical trial failure risk
“Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.” · word for word
Novel modality regulatory uncertainty
“Only one alpha emitting isotope therapy, Xofigo, ... has been approved in the United States or the European Union” · word for word
30 Mar 20268-K · 2.02Cash and equivalents $227M (-24% y/y); revenue $6M (+333% y/y); ipo net proceeds $335Mearningsopen
Figures in the filing · each found in the filing text
| cash_and_equivalents · FY2025 | $227M | -24% y/y |
| revenue · FY2025 | $7M | +333% y/y |
| ipo_net_proceeds · Q1-2026 | $335M |
Risks flagged
Clinical-stage development risk; regulatory approval uncertainties.
“Company is clinical-stage; forward-looking statements highlight risks.”
Aktis Oncology, Inc. — questions
- What did Aktis Oncology, Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Cash, Cash Equivalents and Marketable Securities $517M; Collaboration Revenue $3M; R&D Expenses $25M
Every figure on this page comes from Aktis Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.